Tag Archives: Orphan Drugs

Amid Big Pharma Woes, Shire in “Best Shape Ever”

By Joanna Breitstein | Published: November 17, 2008
Angus Russell, Shire’s longtime CFO—now CEO—likens the failing US automobile industry to pharma. “All the problems with the automobile industry were a long time coming,” he says. “It’s just that the SUVs and the relatively cheap price of gas created a bubble, just like a booming economy and blockbusters.” But now that the bubble has burst, [...]
Posted in Deals, Emerging Markets, R&D, Strategy | Also tagged , | 1 Comment

Linguistics: "Salami-slicing" Orphan Drugs

By Joanna Breitstein | Published: October 23, 2008
Ultra-orphan? It’s a phrase I never heard before, but increasingly, companies are taking it on and finding it a useful way to describe the very smallest patient groups. “Language is very important, and you have to understand how it affects perception,” says Maria Hardin, vice president of patient services for NORD (National Organization for Rare Diseases). [...]
Posted in Events | Also tagged , , , , | 1 Comment